Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
NCT06532565
Recruiting
The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recomm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumors
Register for Updates
A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Research Site 102, Fairfax, Virginia
Conditions: Advanced Solid Tumors
Register for Updates
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981
Recruiting
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Virginia Cancer Specialists, FairFax, Virginia
Conditions: Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer
Register for Updates
The HOPE Study: Characterizing Patients With Hepatitis B and C
NCT02995252
Recruiting
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections w... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/13/2025
Locations: Dr Huong Dang, Medical Practice, Falls Church, Virginia
Conditions: Hepatitis B， Chronic, Hepatitis C
Register for Updates
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
NCT06959706
Recruiting
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumors
Register for Updates
Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study
NCT06874192
Recruiting
Statins are a class of cholesterol lowering medications that contribute to reducing a person's risk of experiencing a cardiovascular event like heart attack. Along with the ability to lower cholesterol, statins also possess anti-inflammatory properties which contribute to their cardioprotective effects. Some people experience side effects while taking statins and are unable to continue treatment with them,which can then increase a person's risk of having cardiovascular issues due to untreated hi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Statin Adverse Reaction
Register for Updates
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
NCT06728059
Recruiting
A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Virginia Center for Diabetes Technology, Charlottesville, Virginia
Conditions: Type 1 Diabetes
Register for Updates
Improving Traumatic Brain Injury Rehab Care With Comm Health Services: a Research Project Within the TBI Model System
NCT06188364
Recruiting
TBI rehabilitation care transitions refer to the processes of preparing patients, families, and community-based healthcare providers for the patient's passage from inpatient rehabilitation to the home and community or to another level of care. Persons with TBI have heterogenous neurological impairment (cognitive and behavioral foremost, along with motor, sensory, and balance), that limits their functional independence and participation, and increases their risk for secondary medical conditions,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Traumatic Brain Injury
Register for Updates
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
NCT06001320
Recruiting
This study is being done to compare the effectiveness of de novo Letermovir versus valganciclovir in preventing the development of cytomegalovirus viremia or symptomatic disease in African American kidney transplant recipients within the first year after transplantation. There are two arms in the study: Arm 1: Prophylaxis: This group includes freshly transplanted high risk (CMV D+/R-) African American Kidney recipients who will be on prophylactic Letermovir for 6 month. Arm 2: Prophylaxis: Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: VCU Medical Center, Richmond, Virginia
Conditions: Kidney Transplant; Complications, CMV
Register for Updates
Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes
NCT05639088
Recruiting
The purpose of this research study is to evaluate a transition preparation program designed for adolescents and young adults (AYAs) with type 1 diabetes (T1D). This transition program will support AYAs as they prepare to transition from pediatric to adult endocrinology medical care and will also include a caregiver. Results from this study will inform clinical recommendations regarding self-management best practices for AYAs with T1D prior to transitioning to adult medical care.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Type 1 Diabetes
Register for Updates
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Sentara Norfolk General Heart Hospital, Norfolk, Virginia
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Register for Updates
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Recruiting
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Register for Updates